New 24-Membered Macrolactines from an Arctic Bacterium Bacillus amyloliquefaciens SCSIO 41392 and Their Anti-Pathogenicity Evaluation.

IF 4.9 2区医学 Q1 CHEMISTRY, MEDICINAL

Marine Drugs Pub Date : 2024-10-28 DOI:10.3390/md22110484

Yue Song, Yachun Zhou, Mengjing Cong, Shengyi Deng, Yushi Chen, Xiaoyan Pang, Yonghong Liu, Li Liao, Liang Yang, Junfeng Wang

{"title":"New 24-Membered Macrolactines from an Arctic Bacterium Bacillus amyloliquefaciens SCSIO 41392 and Their Anti-Pathogenicity Evaluation.","authors":"Yue Song, Yachun Zhou, Mengjing Cong, Shengyi Deng, Yushi Chen, Xiaoyan Pang, Yonghong Liu, Li Liao, Liang Yang, Junfeng Wang","doi":"10.3390/md22110484","DOIUrl":null,"url":null,"abstract":"Three new 24-membered macrolactines, amylomacrolactines A-C (1-3), along with two known compounds 4 and 5, were isolated from the Arctic bacteria Bacillus amyloliquefaciens SCSIO 41392. The configurations of 1-3 were assigned by a combination of coupling constants, NOESY, and analysis of MM2-optimized conformation, as well as by comparison with reports in the literature. Compounds 1 and 2 showed quorum sensing (QS) inhibitory activities against the Pseudomonas aeruginosa (P. aeruginosa) PQS system and suppressed PQS-regulated virulence factor pyocyanin synthesis. In addition, compounds 3-5 affected the production of another essential virulence factor, siderophore of pyoverdine (PVD), in P. aeruginosa. More importantly, compound 5 showed an anti-biofilm activity against P. aeruginosa. Altogether, the isolated compounds displayed multiple bacterial virulence inhibition activities, which is worthy of further exploration for novel analogues in antimicrobial drug development.","PeriodicalId":18222,"journal":{"name":"Marine Drugs","volume":"22 11","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11595553/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marine Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/md22110484","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Three new 24-membered macrolactines, amylomacrolactines A-C (1-3), along with two known compounds 4 and 5, were isolated from the Arctic bacteria Bacillus amyloliquefaciens SCSIO 41392. The configurations of 1-3 were assigned by a combination of coupling constants, NOESY, and analysis of MM2-optimized conformation, as well as by comparison with reports in the literature. Compounds 1 and 2 showed quorum sensing (QS) inhibitory activities against the Pseudomonas aeruginosa (P. aeruginosa) PQS system and suppressed PQS-regulated virulence factor pyocyanin synthesis. In addition, compounds 3-5 affected the production of another essential virulence factor, siderophore of pyoverdine (PVD), in P. aeruginosa. More importantly, compound 5 showed an anti-biofilm activity against P. aeruginosa. Altogether, the isolated compounds displayed multiple bacterial virulence inhibition activities, which is worthy of further exploration for novel analogues in antimicrobial drug development.

查看原文本刊更多论文

北极细菌淀粉样芽孢杆菌（Bacillus amyloliquefaciens SCSIO 41392）中新的 24 位元巨内酯及其抗病原性评估。

从北极细菌淀粉样芽孢杆菌 SCSIO 41392 中分离出了三种新的 24 元大内酯，即淀粉样大内酯 A-C（1-3），以及两种已知化合物 4 和 5。通过耦合常数、NOESY、MM2-优化构象分析以及与文献报道的比较，确定了 1-3 的构型。化合物 1 和 2 对铜绿假单胞菌（P. aeruginosa）PQS 系统显示出法定量感应（QS）抑制活性，并抑制了 PQS 调节的毒力因子焦花青素的合成。此外，化合物 3-5 还影响了铜绿假单胞菌中另一种重要毒力因子--苷元吡咯烷酮（PVD）的产生。更重要的是，化合物 5 对铜绿假单胞菌具有抗生物膜活性。总之，分离出的化合物显示出多种抑制细菌毒力的活性，值得在抗菌药物开发中进一步探索新的类似物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Marine Drugs 医学-医药化学

CiteScore

9.60

自引率

14.80%

发文量

671

审稿时长

1 months

期刊介绍： Marine Drugs (ISSN 1660-3397) publishes reviews, regular research papers and short notes on the research, development and production of drugs from the sea. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible, particularly synthetic procedures and characterization information for bioactive compounds. There is no restriction on the length of the experimental section.